Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 27, 2015 4:05 AM ET

Pharmaceuticals

Company Overview of Apotex Inc.

Company Overview

Apotex Inc., a pharmaceutical company, engages in the research and development, manufacture, distribution, and sale of generic pharmaceuticals in Canada and internationally. It offers medicines in various dosage forms. The company serves patients, healthcare providers, payers, and governments. It offers its products through pharmacies and healthcare facilities. Apotex Inc. has a strategic alliance with Panacea Biotec. The company was founded in 1974 and is based in Toronto, Canada with additional offices in Saudi Arabia. It has facilities in Montreal, Richmond Hill, Toronto, Etobicoke, Mississauga, Brantford, Windsor, Winnipeg, London, Calgary, and Vancouver, Canada; and subsidiaries, joint ...

150 Signet Drive

Toronto, ON M9L 1T9

Canada

Founded in 1974

Phone:

800-268-4623

Fax:

800-609-9444

Key Executives for Apotex Inc.

Chief Executive Officer and President
Founder and Chairman of the Board
President of Apotex International
President of Global Generics
President of Global Specialty Pharma
Compensation as of Fiscal Year 2014.

Apotex Inc. Key Developments

Apotex Announces Structural Realignment

Apotex Inc. has announced realignment in its structure and operating model. The objective of the realignment is to better serve customers through the establishment of defined lines of business by aligning internal process streams in support of company strategies. Under the new structure, Apotex will now operate along 3 core Lines of Business: Global Generics; Global Specialty Pharma; and Global Active Pharmaceutical Ingredients. Global Generics is responsible for the delivery of the generics portfolio arising out of the Apotex group of companies and third parties to all global markets. Global Specialty Pharma is responsible for the development, manufacturing and global commercialisation of Biosimilars and other specialty products made by Apotex or supplied by third parties.

Apotex Inc. Announces Realignment; Announces Executive Appointments

Apotex Inc. announced a significant realignment in its structure and operating model. The objective of the realignment is to better serve customers through the establishment of defined lines of business by aligning internal process streams in support of company strategies. Under the new structure, Apotex will now operate along 3 core Lines of Business: Global Generics: Responsible for the delivery of the generics portfolio arising out of the Apotex group of companies and third parties to all global markets. Global Specialty Pharma: Responsible for the development, manufacturing and global commercialisation of Biosimilars and other specialty products made by Apotex or supplied by third parties. Global Active Pharmaceutical Ingredients (API): Responsible for delivering API to the Apotex Group and sales of select API's to other global customers. The company announced the following appointments to lead the 3 Lines of Business, reporting to Dr. Desai. Effective April 1, 2015: Jeff Watson, currently President of US & Canada Commercial, will take on the role of President Global Generics; Steve Lydeamore, currently Chief Business Officer and Managing Director International, will take on the role of President Global Specialty Pharma; and Dr. Keshava Murthy will continue in his role of President Global API.

US Food and Drug Administration Accepts for Filing of Apotex Inc. Biosimilar Application for Filgrastim

Apotex Inc. announced that, as of February 13, 2015, the US Food and Drug Administration has accepted for filing the company's application for Filgrastim, a biosimilar version of Amgen's Neupogen®. This product has been jointly developed with Intas Pharmaceuticals Ltd. This is the second follow-on biologic FDA submission for Apotex via the 351(k) abbreviated approval pathway created by the Biosimilar Price Competition and Innovation Act (BPCIA). Apotex also has a 351k biosimilar application for the long acting pegylated formulation of filgrastim currently under FDA review. Apotex is the only company to date to have two biosimilar filgrastim applications (pegfilgrastim and filgrastim) currently under active review by FDA. Filgrastim is used to help cancer patients taking chemotherapies fight infections and fever by boosting white blood cell counts. The product will be marketed in the United States by ApoBiologix.

Similar Private Companies By Industry

Company Name Region
NeurAxon Inc. Americas
Insymbiosis Discovery Inc. Americas
Squire Pharmaceuticals Inc. Americas
DRAXIMAGE, Inc. Americas
TSASA Holdings Inc. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Apotex Inc., please visit www.apotex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.